Wyeth’s Conbriza recommended for EU approval

2/20/2009

COLLEGEVILLE, Pa. The Committee for Medicinal Products for Human Use , the scientific committee of the European Medicines Agency, on Thursday adopted a positive opinion recommending to grant a marketing authorization for Conbriza (bazedoxifene) for the treatment of postmenopausal osteoporosis in women at increased risk of fracture. Conbriza, an investigational medicine, is in development by Wyeth Pharmaceuticals.

"If approved, Wyeth believes that Conbriza could be an important new treatment option for physicians and their patients," stated Gary Stiles, EVP and chief medical officer, Wyeth Pharmaceuticals. "More therapeutic options are needed for postmenopausal women with osteoporosis, particularly for those at increased risk of fracture. Wyeth remains committed to women's health care, and Conbriza is an important affirmation of that commitment."

The CHMP is responsible for reviewing medicinal product applications for safety, quality and efficacy. The Committee's positive opinion will be forwarded to the European Commission for a final decision. Final approval customarily follows the CHMP's recommendation and is expected in approximately 60 days.

Wyeth intends to introduce Conbriza in Europe following receipt of necessary reimbursement authorizations. Wyeth is also pursuing regulatory approval of bazedoxifene for the prevention and treatment of postmenopausal osteoporosis in the United States.

X
This ad will auto-close in 10 seconds